NCT00612417View on ClinicalTrials.gov

Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

March 31, 2008

Study Completion Date

June 30, 2008

Conditions
Healthy
Interventions
DRUG

Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402

Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402

Trial Locations (1)

DK-2100

Cyncron CRU, Copenhagen

Sponsors

Lead Sponsor

ThromboGenics
All Listed Sponsors
collaborator

BioInvent International AB

INDUSTRY

lead

ThromboGenics

INDUSTRY